FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: Multicentric study

Annals of Oncology

Volumn 21, Issue 9, 2010, Pages 1877-1883

  Lopci, E ^a   Santi, I ^a   Derenzini, E ^a   Fonti, C ^a   Savelli, G ^b   Bertagna, F ^b   Bello M ^c   Botto, B ^c   Huglo, D ^d   Morschhauser, F ^d   Zinzani, P ^a   Fanti, S ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Spedali Civili ^*  (Italy)

^c MOLINETTE HOSPITAL   (Italy)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Follicular lymphoma; Ibritumomab tiuxetan Y 90; Non Hodgkin's lymphoma; PET; Radioimmunotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; FLUORODEOXYGLUCOSE F 18; IBRITUMOMAB TIUXETAN; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 77956097936     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq024     Document Type: Article

References (29)

1. Talbot JN, Haioun C, Rain JD. [18F]-FDG positron imaging in clinical management of lymphoma patients. Crit Rev Oncol Hematol 2001; 38: 193-221.
2. Hutchings M, Specht L. PET/CT in the management of haematological malignancies. Eur J Haematol 2008; 80(5): 369-380.
3. Wohrer S, Jaeger U, Kletter K et al. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 2006; 17: 780-784.
4. Jerusalem G, Beguin Y, Najjar F et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001; 12(6): 825-830.
5. Zinzani PL, Musuraca G, Alinari L et al. Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. Clin Lymphoma Myeloma 2007; 7(4): 291-295.
6. Grillo-Lopez AJ. Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev Anticancer Ther 2002; 2: 485-493.
7. Joyce JM, Degirmenci B, Jacobs S et al. FDG PET CT assessment of treatment response after yttrium-90 ibritumomab tiuxetan radioimmunotherapy. Clin Nucl Med 2005; 30(8): 564-568.
8. Papajik T, Prochazka V, Raida L et al. Relapsed follicular lymphoma sequentially treated with rituximab and 90Y-ibritumomab tiuxetan. Case report. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2007; 151(1): 109-112.
9. Ulaner GA, Colletti PM, Conti PS. B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy-initial experience. Radiology 2008; 246: 895-902.
10. Jacene HA, Filice R, Kasecamp W et al. 18F-FDG PET/TC for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med 2009; 50(1): 8-17.
11. DeMonaco NA, Jacobs SA. Serum sickness in a patient with follicular lymphoma after rituximab and radioimmunotherapy with ibritumomab tiuxetan. Clin Nucl Med 2007; 32(12): 933-934.
12. Jacene HA, Filice R, Kasecamp W et al. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med 2007; 48: 1767-1776.
13. Tennvall J, Fischer M, Bischof Delaloye A et al. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging 2007; 34(4): 616-622.
14. Carbone PP, Kaplan HS, Musshoff K et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860-1861.
15. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25(5): 579-586.
16. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 456-481.
17. Mantel N. Evaluation of survival data and two new rank order arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
18. Witzig TE, White CA, Wiseman GA et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793-3803.
19. Witzig TE, Gordon LI, Cabanillas F et al. Randomised controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-2463.
20. Witzig TE, Molina A, Gordon LI et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007; 109(9): 1804-1810.
21. Wagner HN Jr, Wiseman GA, Marcus CS et al. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 2002; 43: 267-272.
22. Shipley DL, Spigel DR, Carrell DL et al. Phase II trial of rituximab and short duration chemotherapy followed by 90Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: a Minnie Pearl Cancer Research Network phase II trial [abstract]. Proc Am Soc Clin Oncol 2004; 23: 560.
23. Emmanouilides C, Witzig TE, Gordon LI et al. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2006; 47: 629-636.
24. Zinzani PL, D'Amore F, Bombardieri E et al. Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice-report of a European workshop. Eur J Cancer 2008; 44(3): 366-373.
25. Gordon LI, Molina A, Witzig T et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of phase 1/2 study. Blood 2004; 103(12): 4429-4431.
26. Gregory SA, Leonard J, Vose J et al. Superior outcomes associated with earlier use: experience with tositumomab and iodine I 131 tositumomab in 1,177 patients (pts) with low-grade follicular, and transformed non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 2005; 23: 585 (Abstr 6561).
27. Emmanouilides C. Radioimmunotherapy for non-Hodgkin lymphoma: historical prospective and current status. J Clin Exp Hematopathol 2007; 47(20): 43-60.
28. Juweid ME, Wiseman GA, Vose JM et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005; 23(21): 4652-4661.
29. Juweid ME, Stroobants S, Hoekstra OS et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571-578.